Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus

Diabetologia

Volumn 58, Issue 1, 2015, Pages 188-198

  Fufaa, Gudeta D ^a   Weil, E Jennifer ^a   Nelson, Robert G ^a   Hanson, Robert L ^a   Bonventre, Joseph V ^b   Sabbisetti, Venkata ^b   Waikar, Sushrut S ^b   Mifflin, Theodore E ^c   Zhang, Xiaoming ^d   Xie, Dawei ^d   Hsu, Chi yuan ^e   Feldman, Harold I ^d,f   Coresh, Josef ^g,h   Vasan, Ramachandran S ⁱ   Kimmel, Paul L ^a   Liu, Kathleen D ^e  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; End stage renal disease; Mortality; Type 2 diabetes

Indexed keywords

CREATININE; FATTY ACID BINDING PROTEIN; KIDNEY INJURY MOLECULE 1; LIVER FATTY ACID BINDING PROTEIN; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; FABP1 PROTEIN, HUMAN; HAVCR1 PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; LIPOCALIN; MEMBRANE PROTEIN; NAG PROTEIN, HUMAN; ONCOPROTEIN; TUMOR PROTEIN; VIRUS RECEPTOR;

ADULT; ALBUMINURIA; AMERICAN INDIAN; ARTICLE; DEATH; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; URINALYSIS; ADOLESCENT; AGED; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETIC NEPHROPATHY; ETHNOLOGY; INCIDENCE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; URINE; YOUNG ADULT;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FATTY ACID-BINDING PROTEINS; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 1; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; KIDNEY FAILURE, CHRONIC; LIPOCALIN-2; LIPOCALINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; YOUNG ADULT;

EID: 84916198679     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3389-3     Document Type: Article

References (46)

1. U.S. Renal Data System (2013) USRDS 2013 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
2. Araki S, Haneda M, Sugimoto T et al (2005) Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54:2983–2987
3. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285–2293
4. Pavkov ME, Knowler WC, Hanson RL, Bennett PH, Nelson RG (2008) Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. Am J Kidney Dis 51:759–766
5. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O (2004) Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19:2784–2788
6. Fioretto P, Mauer M, Brocco E et al (1996) Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569–1576
7. Nosadini R, Velussi M, Brocco E et al (2000) Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49:476–484
8. Bolignano D, Lacquaniti A, Coppolino G et al (2009) Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4:337–344
9. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P (2010) Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 33:1320–1324
10. Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P (2011) Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 79:1113–1118
11. von Eynatten M, Baumann M, Heemann U et al (2010) Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 40:95–102
12. Nielsen SE, Hansen HP, Jensen BR, Parving HH, Rossing P (2011) Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study. Nephron Clin Pract 118:130–135
13. Vaidya VS, Niewczas MA, Ficociello LH et al (2011) Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-d-glucosaminidase. Kidney Int 79:464–470
14. Nielsen SE, Reinhard H, Zdunek D et al (2012) Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 97:71–76
15. Kim SS, Song SH, Kim IJ et al (2012) Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract 97:251–257
16. Fu WJ, Li BL, Wang SB et al (2012) Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract 95:105–109
17. Conway BR, Manoharan D, Manoharan D et al (2012) Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors. Kidney Int 82:812–818
18. Liu KD, Yang W, Anderson AH et al (2013) Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int 83:909–914
19. Araki S, Haneda M, Koya D et al (2013) Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 36:1248–1253
20. O’Seaghdha CM, Hwang SJ, Larson MG, Meigs JB, Vasan RS, Fox CS (2013) Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J Am Soc Nephrol 24:1880–1888
21. Chou KM, Lee CC, Chen CH, Sun CY (2013) Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PLoS One 8:e54863
22. Panduru NM, Forsblom C, Saraheimo M et al (2013) Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 36:2077–2083
23. Kamijo-Ikemori A, Sugaya T, Yasuda T et al (2011) Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 34:691–696
24. Nelson RG, Bennett PH, Beck GJ et al (1996) Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 335:1636–1642
25. Weil EJ, Fufaa G, Jones LI et al (2013) Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 62:3224–3231
26. Myers BD, Nelson RG, Tan M et al (1995) Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 47:1781–1789
27. Pencina MJ, D’Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109–2123
28. Demler OV, Pencina MJ, D’Agostino RB Sr (2012) Misuse of DeLong test to compare AUCs for nested models. Stat Med 31:2577–2587
29. Pepe MS, Kerr KF, Longton G, Wang Z (2013) Testing for improvement in prediction model performance. Stat Med 32:1467–1482
30. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Comments on integrated discrimination and net reclassification improvements: practical advice. Stat Med 27:207–212
31. Pencina MJ, D’Agostino RB, Pencina KM, Cecile A, Janssens JW, Greenland P (2012) Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 176:473–481
32. Thraikill KM, Moreau CS, Cockrell GE (2010) Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 37:336–343
33. Meunier-Durmort C, Poirier H, Niot I, Forest C, Besnard P (1996) Up-regulation of the expression of the gene for liver fatty acid-binding protein by long-chain fatty acids. Biochem J 319:483–487
34. Kamijo A, Sugaya T, Hikawa A et al (2004) Urinary excretion of fatty-acid binding protein reflects stress overload on the proximal tubules. Am J Pathol 165:1243–1255
35. Coca SG, Garg AX, Thiessen-Philbrook H et al (2014) Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J Am Soc Nephrol 25:1063–1071
36. Tramontia G, Kanwar Y (2011) Tubular biomarkers to assess progression of diabetic nephropathy. Kidney Int 79:1042–1044
37. Xu S, Venge P (2000) Lipocalins as biochemical markers of disease. Biochim Biophys Acta 1482:298–307
38. Zoja C, Benigni A, Remuzzi G (2004) Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens 13:31–37
39. Sharma SG, Bomback AS, Radhakrishnan J et al (2013) The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 8:1718–1724
40. Helmersson-Karlqvist J, Larsson A, Carlsson AC et al (2013) Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with mortality in a community-based cohort of older Swedish men. Atherosclerosis 227:408–413
41. Yoshikawa K, Adachi H, Hirai Y et al (2013) High serum N-acetyl-ß-d-glucosaminidase activity is a predictor of 28-year mortality in a population of community-dwelling Japanese-the Tanushimaru study. J Am Geriatr Soc 61:467–468
42. Jungbauer CG, Birner C, Jung B et al (2011) Kidney injury molecule-1 and N-acetyl-β-d-glucosaminidase in chronic heart failure: a possible biomarker of cardiorenal syndrome. Eur J Heart Fail 13:1104–1110
43. Sarnak MJ, Katz R, Newman A et al (2014) Association of urinary injury biomarkers with mortality and cardiovascular events. J Am Soc Nephrol 25:1545–1553
44. Han WK, Wagener G, Zhu Y, Wang S, Lee HT (2009) Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 4:873–882
45. Nielsen SE, Schjoedt KJ, Astrup AS et al (2010) Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 27:1144–1150
46. Nielsen SE, Rossing K, Hess G et al (2012) The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. Scand J Clin Lab Invest 72:137–142